UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
report (Date of earliest event reported): February 1,
2010
IMMUNOSYN
CORPORATION
(Exact
Name of Registrant as Specified in Charter)
|
Delaware
|
005-82677
|
20-5322896
|
|
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File
Number)
|
(I.R.S.
Employer
Identification
No.)
|
10815
Rancho Bernardo Road, Suite 101,
San
Diego, CA 92127
(Address
of Principal Executive Offices and Zip Code)
(888)
853-3663
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the
Form 8-K is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2.
below):
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14A-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
SECTION
8 – Other Events
Item
8.01. Other Events.
A complaint
(the "Complaint") was filed on August 25, 2009 by Myron W. Wentz, a shareholder
of Immunosyn Corporation (the “Company” or “Immunosyn”), in the United
States District Court for the Southern District of California that named as
defendants Argyll Biotechnologies, LLC (“Argyll Biotech”), the
Company and Does 1-10. The Complaint alleged, among other
things, that Argyll Biotech breached its contract with the plaintiff and
that the Company tortiously interfered with Argyll Biotech’s contract with
the plaintiff. The Complaint sought damages in the amount of $1,948,000
plus pre- and post-judgment interest; consequential damages and attorneys
fees in an amount to be proven at trial against Argyll Biotech for breach of
contract; an Order compelling Argyll Biotech to provide 14,984,615
shares of common stock of the Company to Dr. Wentz; and attorneys fees
in an amount to be proven at trial.
On
February 1, 2010, a default judgment was entered against Immunosyn in favor of
the plaintiff, Dr. Wentz, in the United States District Court for the Southern
District of California in the amount of $1,948,000.00 plus post-judgment
interest in accordance with the law.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly
authorized.
Dated: February
12,
2010
IMMUNOSYN CORPORATION
By: /s/ Douglas A. McClain,
Jr.
Douglas
A. McClain, Jr.
Chief
Financial and Accounting Officer